Close Menu

MRSA

Collaborators said that the test is accurate and reliable for the rapid detection of the most common gram-positive bacteria responsible for bloodstream infections.

At the recent CVS, the two large health systems described introducing Cepheid platforms for flu testing across rural and satellite locations.

A rapid PCR respiratory panel enabled the hospital to avoid antibiotics in 89 out of 295 pediatric patients in a one-year period.

Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.

Performed on the company's Safetube platform, GFC's Microscreen test uses DNA hybridization to detect biomarkers in methicillin-resistant Staphylococcus aureus.

The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals. 

The test, which simultaneously detects MRSA and Staphylococcus aureus, is designed to run on the company's Liat PCR point-of-care platform.

Scientists have shown that the test provides specific results in around one minute and can be adapted to detect several other pathogens.

To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.

Abaxis claims that Cepheid's PCR-based blood test for methicillin-resistant Staphylococcus aureus infringes its sample prep patents. In response, Cepheid has filed a counterclaim denying the alleged infringement and asking the court to find that Abaxis' patents are invalid.

Pages